Drug Profile
Bicyclol
Alternative Names: SY 801Latest Information Update: 25 Sep 2021
Price :
$50
*
At a glance
- Originator Chinese Academy of Medical Sciences
- Developer Beijing Union Pharmaceutical; Chinese Academy of Medical Sciences
- Class Antineoplastics; Antivirals; Biphenyl compounds; Hepatoprotectants; Small molecules
- Mechanism of Action Cytochrome P-450 enzyme system stimulants; Free radical scavengers; Gap junction modulators; Glutathione transferase stimulants; HSP70 heat shock protein stimulants; Protein kinase C inhibitors; Proto-oncogene protein c-myc stimulants; Ras protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Fatty liver; Viral hepatitis
- No development reported Liver cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Liver-cancer in China (PO, Tablet)
- 13 Jul 2015 Bicyclol is covered by patent protection (Beijing Union website, July 2015)
- 18 Nov 1996 Preclinical development for Viral hepatitis in China (Unknown route)